Patents by Inventor Michael Ollmann

Michael Ollmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20230279399
    Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 7, 2023
    Applicant: Amgen Inc.
    Inventors: Daniel C. H. LIN, Michael OLLMANN, Justin K. MURRAY, Bradley J. HERBERICH, Amrita DAS, Patrick COLLINS, Oliver HOMANN
  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 11732266
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 22, 2023
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul, Yuan Cheng
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
    Publication number: 20230078200
    Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 16, 2023
    Applicant: AMGEN INC.
    Inventors: Bin WU, Michael OLLMANN, Oliver HOMANN, Yuan CHENG
  • RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20220307022
    Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 29, 2022
    Applicant: AMGEN INC.
    Inventors: Amrita DAS, Bradley J. HERBERICH, Justin K. MURRAY, Oliver HOMANN, Michael OLLMANN, Daniel C.H. LIN
  • RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20220017906
    Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: December 10, 2019
    Publication date: January 20, 2022
    Applicant: Amgen Inc.
    Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
  • RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20210139912
    Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: December 12, 2018
    Publication date: May 13, 2021
    Applicant: AMGEN INC.
    Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20210108212
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 15, 2021
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 10870856
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 22, 2020
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20190309306
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: August 25, 2017
    Publication date: October 10, 2019
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • Cdk9 as Modifier of the Igf Pathway and Methods of Use
    Publication number: 20080095763
    Abstract: Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: April 24, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Mark Maxwell, Michael Ollmann, Timothy Heuer, Lynn Bjerke
  • Mptens as Modifiers of the Pten/Igf Pathway and Methods of Use
    Publication number: 20070274914
    Abstract: Human MPTEN genes are identified as modulators of the PTEN/IGF pathway, and thus are therapeutic targets for disorders associated with defective PTEN/IGF function. Methods for identifying modulators of PTEN/IGF, comprising screening for agents that modulate the activity of MPTEN are provided.
    Type: Application
    Filed: May 13, 2004
    Publication date: November 29, 2007
    Inventors: Chunyan Song, Michael Ollmann, Kim Lickteig, HaiGuang Zhang, Lynn Bjerke
  • Ranbp2 as Modifiers of the Pten/Igf Pathway and Methods of Use
    Publication number: 20070269802
    Abstract: Human RANBP2 genes are identified as modulators of the PTEN/IGF pathway, and thus are therapeutic targets for disorders associated with defective PTEN/IGF function. Methods for identifying modulators of FEN/IGF, comprising screening for agents that modulate the activity of RANBP2 are provided.
    Type: Application
    Filed: May 13, 2004
    Publication date: November 22, 2007
    Applicant: Exelixis, Inc.
    Inventors: Chunyan Song, Michael Ollmann, Kim Lickteig